The administration of aromatase inhibitors (AI) in endometriosis patients may directly decrease aromatase activity in endometriotic tissue and estrogen level, thereby suppressing COX-2 activity, decreasing PGE2 level, and breaking the positive feedback loop (35,36,37,38). The gene discussed is CYP19A1; the disease is endometriosis.